Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (8802)	6/24/2005 1:41:54 PM
From: Jibacoa	Read Replies (2) \| Respond to of 23958

Re: Stem Cells As you know, last month the House passed a bill that may ease the restrictions imposed by President Bush and the Senate could also vote on a similar bill next month.Question is wether the President would veto it. However, funding from the private sector and several states seems to be alive and well. There are 4 companies that are mainly involved and are showing some up-moves today.<g>: VIAC, which has some help from AMGN and GENZ and is getting some revenue from storing umbilical cord cells from individuals which has potential, among other things, for use like a "bone marrow" transplant. Is trying to get over its June 20 H at 9.73 bigcharts.marketwatch.com GERN, which was one of the first in the field and this week has been presenting at the ISSCR annual meeting in San Francisco,on its new hESC lines. Already oligodendroglial progenitor cells derived from hESCs and transplanted into mice with spinal cord injuries have shown some signs of recovery and evidence of axonal remyelination. It is probably GERN's leading product. They are also working on the further differentiation of hESCs for the production of cardiomyocytes, hepatocytes, insulin secreting clusters, and other products, which of course are still some years from clinical use or getting FDA approvals.<g> GERN is also working on a "cancer vaccine" and has some relations with scientists at the UW at Madison where James Thomson fist isolated stem cells in 1998. Still has to deal with the resistance above 8.05 bigcharts.marketwatch.com STEM , which presented at the Morgan Stanley Small Cap Conference in NY last week, is also working on Parkinson's, AD, and other neurodegenerative diseases, as well as on MS, strokem hepatitis,spinal cord injuries,liver failure,diabetes and others.Their Debt/Equt. ratio is around 0.06 so they probably can continue to burn cash for a while longer without an inmediate infusion.<g> Waiting for it to go over 4.35 bigcharts.marketwatch.com ASTM ,which is trying to go over the resistance at $3 in spite of the insiders' sales last month by its Chairman and CEO, Dr. R. Douglas Armstrong, as was also pointed out today by the Motley Fool.<g> The June 15 H was 3.11 bigcharts.marketwatch.com Bernard